TRC102 is intended to reverse resistance to Temodar chemotherapy by targeting a specific DNA repair pathway. The Phase I trial is designed to assess the safety, tolerability and
The first AZ-004 Phase III clinical trial is designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 US clinical centers. The trial is an in-clinic,
Harris will provide advanced imaging and information systems that assure critical medical information is delivered with accuracy, speed, security and privacy. Jeff Shogan, managing director and chairman of
The randomized, double-blind study is designed to evaluate the safety and efficacy of Ammonul versus standard of care in hospitalized adults. The FDA has granted Ammonul orphan drug
The company is reportedly considering splitting its biopharmaceuticals arm, which markets its multiple sclerosis drug Tysabri, from EDT. According to the publication, Elan could boost the value of
Eucreas is a combination of metformin, which decreases the production of sugar by the liver and increases insulin sensitivity, and galvus, a member of DPP-4 inhibitors associated with
The acquisition brings together Cypress’s drug development expertise, commercial resources and lead pharmaceutical candidate, milnacipran, which is currently under FDA review for the treatment of fibromyalgia, and Proprius’s
The company plans to include 180 patients in the study at around 20 clinics in Sweden. The results from the trial are expected in the second half of
The primary objective of the study is to determine the progression-free survival of patients with previously untreated and inoperable liver cancer when treated with IMC-1121B. This Phase II
Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. This approval follows the successful
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.